# Comparative Review on Cancer Pathology from Aberrant Histone Chaperone Activity

## TL;DR

This review explores how abnormal histone chaperone activity contributes to cancer and highlights their potential as targets for new cancer therapies.

## Contribution

The paper systematically reviews the role of histone chaperones in cancer pathogenesis and their potential as therapeutic targets.

## Key findings

- Dysregulation of histone chaperones is linked to tumorigenesis and cancer progression.
- Altered histone chaperone activity correlates with genomic instability and oncogenic processes.
- Histone chaperones are viable targets for precision cancer therapies.

## Abstract

Histone chaperones are integral to chromatin dynamics, facilitating the assembly and disassembly of nucleosomes, thereby playing a crucial role in regulating gene expression and maintaining genomic stability. Moreover, they prevent aberrant histone interactions prior to chromatin assembly. Disruption in histone chaperone function may result in genomic instability, which is implicated in pathogenesis. This review aims to elucidate the role of histone chaperones in cancer pathologies and explore their potential as therapeutic targets. Histone chaperones have been found to be dysregulated in various cancers, with alterations in expression levels, mutations, or aberrant interactions leading to tumorigenesis and cancer progression. In addition, this review intends to highlight the molecular mechanisms of interactions between histone chaperones and oncogenic factors, underscoring their roles in cancer cell survival and proliferation. The dysregulation of histone chaperones is significantly correlated with cancer development, establishing them as active contributors to cancer pathology and viable targets for therapeutic intervention. This review advocates for continued research into histone chaperone-targeted therapies, which hold potential for precision medicine in oncology. Future advancements in understanding chaperone functions and interactions are anticipated to lead to novel cancer treatments, enhancing patient care and outcomes.